EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers

Eva Ellebaek, Marco Donia, Inge Marie Svane

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Eva Ellebaek und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Immunotherapy, Melanoma, Neoadjuvant Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation, Independent Research Fund Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Groundbreaking studies have reshaped the treatment landscape for patients with resectable stage ≥IIIB melanoma by demonstrating the benefits of neoadjuvant therapy. Data from the NADINA and SWOG S1801 trials reveal substantial improvements in event-free survival compared to adjuvant therapy alone. These studies employed distinct neoadjuvant immunotherapy approaches - ipilimumab plus nivolumab in NADINA and anti-PD-1 monotherapy in SWOG S1801 - highlighting potential differences in efficacy and toxicity. The integration of biomarkers may improve the risk/benefit ratio by enabling personalized treatment selection between ipilimumab plus nivolumab versus anti-PD-1 monotherapy. In metastatic melanoma, molecular biomarkers such as BRAF mutational status and intratumoral PD-L1 expression can help guide treatment decisions; however, their, and other biomarkers', role in the neoadjuvant context has yet to be fully investigated. This commentary underscores the need to investigate whether these molecular markers, along with other biomarkers and clinical parameters, can inform neoadjuvant therapy in resectable stage ≥IIIB melanoma. We propose a coordinated effort involving retrospective analyses of current trials and prospective clinical studies, to define the role of biomarkers. A biomarker-guided approach could optimize efficacy and reduce toxicity, offering personalized treatment options for patients with resectable melanoma. As implementation of neoadjuvant therapy rapidly gains global adoption, we advocate for robust research to ensure that each patient receives the most effective and least toxic therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorImmunotherapyMelanomaNeoadjuvant TherapySkin NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

BiomarkersImmunotherapyMelanomaNeoadjuvantPD-L1Perioperative

Substanzen

Biomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Electronic address: marco.donia@regionh.dk.
  • National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Electronic address: inge.marie.svane@regionh.dk.

Förderung

  • Novo Nordisk Foundation
  • Independent Research Fund Denmark

Zitieren

APA

Ellebaek, E., Donia, M., & Svane, I. M. (2025). Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115257

Vancouver

Ellebaek E, Donia M, Svane IM. Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115257

BibTeX
@article{Ellebaek2025,
  author = {Ellebaek, Eva and Donia, Marco and Svane, Inge Marie},
  title = {Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115257}
}
Kostenlos starten →